Piemonti, Lorenzo
Landoni, Giovanni
Voza, Antonio
Puoti, Massimo
Gentile, Ivan
Coppola, Nicola
Nava, Stefano
Mattei, Alessia
Marinangeli, Franco
Marchetti, Giulia
Bonfanti, Paolo
Mastroianni, Claudio Maria
Bassetti, Matteo
Crisafulli, Ernesto
Grossi, Paolo Antonio
Zangrillo, Alberto
Desai, Antonio
Merli, Marco
Foggia, Maria
Carpano, Marco
Schiavoni, Lorenzo
D’Arminio Monforte, Antonella
Bisi, Luca
Russo, Gianluca
Busti, Fabiana
Rovelli, Cristina
Perrotta, Elisabetta
Goisis, Giovanni
Gavioli, Elizabeth M.
Toya, Sophie
De Pizzol, Maria
Mantelli, Flavio
Allegretti, Marcello
Minnella, Enrico Maria
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia: A Phase 3, Randomized, Double-Blind Placebo-Controlled Study
https://doi.org/10.1007/s40121-023-00871-5
Funding for this research was provided by:
Dompé farmaceutici SpA
Article History
Received: 29 May 2023
Accepted: 6 September 2023
First Online: 5 October 2023
Declarations
:
: Lorenzo Piemonti has no other conflicts of interest to disclose. Giovanni Landoni has no other conflicts of interest to disclose. Antonio Voza declares consulting fees from Sildeha Pharma Swisse; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Minerva Medica and Viatris; payment for expert testimony from GlaxoSmithKline, Alfa Sigma (to his institution), and Aurora Biopharma; and unpaid roles as guest editor of special issue on COVID-19: Prognosis and Long-term Sequelae’ on Viruses, and an advisory board for Critical Reviews in Oncology/Hematology, all outside the scope of the current manuscript. Massimo Puoti declares payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Gilead Sciences, GlaxoSmithKline, and AstraZeneca, all outside the scope of the current manuscript. Ivan Gentile declares departmental grants from Gilead; personal fees and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from MSD, AbbVie, Gilead, Pfizer, GlaxoSmithKline, SOBI, Nordic/InfectoPharm, Angelini, Abbott, and Basilea; support for attending a meeting from Janssen and Gilead; and participation on a data safety monitoring board or advisory board for MSD, AbbVie, Gilead, Pfizer, GlaxoSmithKline, SOBI, Nordic/InfectoPharm, Angelini, Abbott, and Basilea, all outside the scope of the current manuscript. Nicola Coppola has no other conflicts of interest to disclose. Stefano Nava has no other conflicts of interest to disclose. Alessia Mattei has no other conflicts of interest to disclose. Franco Marinangeli declares payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Grunenthal, Mundipharma, and MSD, all outside the scope of the current manuscript. Giulia Marchetti declares payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Gilead, ViiV, MSD, Shionogi, and Angelini; support for attending meetings and/or travel from Jannsen and ViiV; and participation on a data safety monitoring board or advisory board for Viiv and Gilead, all outside the scope of the current manuscript. Paolo Bonfanti declares consulting fees and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Viiv, Gilead, Merck, Jannsen, and Pfizer, all outside the scope of the current manuscript. Claudio Maria Mastroianni declares consulting fees from Gilead and VIIV; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from MSD, VIIV, Gilead, Menarini, AstraZeneca, and Pfizer; and support for attending meetings and/or travel from Menarini, all outside the scope of the current manuscript. Matteo Bassetti declares payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Angelini, Astellas, Bayer, Biomerieux, Cidara, Gilead, Menarini, MSD, Nabriva, and Shionogi, and participation on a data safety monitoring board or advisory board for Angelini, Astellas, Bayer, Biomerieux, Cidara, Gilead, Menarini, MSD, Nabriva, and Shionogi, all outside the scope of the current manuscript. Ernesto Crisafulli declares a grant from GlaxoSmithKline; honoraria for lecturing for AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini, Qbgroup, and Sanofi; honoraria for scientific advisory boards for Chiesi and GlaxoSmithKline; and support for attending meetings and/or travel from Chiesi and GlaxoSmithKline, all outside the scope of the current manuscript. Paolo Antonio Grossi declares consulting fees from Takeda, MSD, and Gilead; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Biotest and Gilead; and participation on a data safety monitoring board or advisory board for Reithera, all outside the scope of the current manuscript. Alberto Zangrillo has no other conflicts of interest to disclose. Antonio Desai has no other conflicts of interest to disclose. Marco Merli declares grants or contracts from Gilead, and support for attending meetings and/or travel from Pfizer, all outside the scope of the current manuscript. Maria Foggia has no other conflicts of interest to disclose. Marco Carpano has no other conflicts of interest to disclose. Lorenzo Schiavoni has no other conflicts of interest to disclose. Antonella D’Arminio Monforte has no other conflicts of interest to disclose. Luca Bisi has no other conflicts of interest to disclose. Gianluca Russo declares support for attending a meeting from Gilead, outside the scope of the current manuscript. Fabiana Busti has no other conflicts of interest to disclose. Cristina Rovelli has no other conflicts of interest to disclose. Elisabetta Perrotta, Giovanni Goisis, Elizabeth M. Gavioli, Sophie Toya, Maria De Pizzol, Flavio Mantelli, Marcello Allegretti, and Enrico Maria Minnella are employees of Dompé Farmaceutici SpA, the sponsor of the study.
: The study was approved by all institutions and was performed in accordance with the Helsinki Declaration and the International Conference of Harmonization Tripartite Guidelines for Good Clinical Practice (ICH/CPMP/135/95), and was registered at EudraCT (2020-005919-51, 19 January 2021) and ClinicalTrials.gov (NCT04878055, 7 May 2021). All patients provided informed consent to participate in the study.